General University Hospital Of Patras

The Division of Oncology at General University Hospital Of Patras is conducting research on cardiovascular disorders, including acute coronary syndrome, atrial fibrillation and heart failure with preserved ejection fraction. The trials focus on evaluating new anticoagulants, anti‑inflammatory agents and rapid‑action treatments to reduce heart attacks, strokes and related complications.

• Acute coronary syndrome and myocardial infarction
• Atrial fibrillation with risk of stroke
• Heart failure with preserved or mildly reduced ejection fraction
• Oral FXIa inhibitors for secondary stroke prevention
• Platelet‑targeted therapies for post‑ischemic event care

Over 30 active studies and a team of 50 investigators make the site a key contributor to European cardiovascular research initiatives.

Investigators at the hospital are exploring therapeutic options for glaucoma and other ocular conditions. Clinical work aims to preserve visual fields and improve retinal health by testing novel eye‑drop formulations and neuroprotective strategies.

• Open‑angle glaucoma visual field preservation
• Evaluation of citicoline eye drops
• Adjunctive therapies for ocular hypertension

These studies support the development of safer, more effective treatments for patients at risk of vision loss.

The site’s oncology division includes trials addressing female urogenital cancers such as advanced breast and endometrial cancer. Research evaluates extended endocrine therapy, targeted agents and combination regimens to improve disease‑free and overall survival.

• Advanced breast cancer with ER+/HER2‑negative status
• High‑risk endometrial cancer after surgery
• Adjuvant endocrine therapy with novel SERDs

By integrating oncology and gynecologic expertise, the hospital advances personalized care for women with complex malignancies.

Research at General University Hospital Of Patras targets blood‑forming and lymphatic disorders, including myelodysplastic syndromes, multiple myeloma and α‑thalassemia. Trials compare emerging agents with standard therapies to enhance blood cell production and reduce transfusion dependence.

• Lower‑risk myelodysplastic syndromes and anemia management
• New erythroid‑stimulating agents versus epoetin alfa
• Alpha‑thalassemia HbH disease therapeutic dosing
• Relapsed or refractory multiple myeloma combination regimens

These studies aim to improve quality of life and survival for patients with hematologic malignancies and inherited blood disorders.

The hospital conducts investigations into male urogenital malignancies, focusing on high‑risk metastatic hormone‑sensitive prostate cancer. Clinical trials assess the addition of novel androgen‑targeted therapies to standard hormonal regimens.

• Metastatic hormone‑sensitive prostate cancer
• Combination of abemaciclib with abiraterone plus prednisone
• Evaluation of next‑generation androgen receptor degraders

These efforts seek to delay disease progression and extend overall survival for men with advanced prostate cancer.

A broad portfolio of oncology trials at the site addresses solid tumors and hematologic cancers, including breast, lung, bladder and various sarcomas. Studies test innovative targeted therapies, immunotherapies and antibody‑drug conjugates to increase progression‑free and overall survival.

• ER+/HER2‑negative advanced breast cancer with novel SERDs
• Non‑small cell lung cancer with ROS1 or EGFR alterations
• Metastatic squamous NSCLC comparing new TKIs
• Antibody‑drug conjugate versus docetaxel in previously treated NSCLC
• Combination immunotherapy with pembrolizumab in high‑risk endometrial cancer

With 33 active trials, the division contributes substantial data to the global fight against cancer.

The hospital’s research also encompasses systemic conditions such as chronic inflammation and metabolic dysregulation. Trials evaluate anti‑inflammatory biologics and small molecules to reduce cardiovascular risk and improve organ function.

• Ziltivekimab for heart failure with systemic inflammation
• Milvexian versus apixaban for major adverse cardiovascular events
• Assessment of biomarkers in patients with mixed clinical presentations

These investigations aim to translate mechanistic insights into tangible therapeutic benefits for patients with complex, multi‑system disease.

Clinical work in the respiratory field focuses on asthma, COPD and progressive pulmonary fibrosis. Studies compare inhaled corticosteroid/long‑acting bronchodilator combinations, antifibrotic agents and novel oral therapies to improve lung function and reduce exacerbations.

• Asthma treatment in children with indacaterol/mometasone versus budesonide
• Chronic obstructive pulmonary disease exacerbation reduction with tozorakimab
• Progressive pulmonary fibrosis efficacy of oral antifibrotic compounds
• Idiopathic pulmonary fibrosis safety and tolerability assessments

The trials seek to enhance respiratory health and slow disease progression for individuals with chronic lung disorders.